Key Points
- Adam Crystal sold 12,000 shares of Tango Therapeutics at $20.11 on March 25 for $241,320, cutting his stake to 112,622 (a 9.63% reduction); he has sold roughly 105,048 shares across four recent transactions, raising about $1.47M.
- TNGX trades near $19.26 with a market cap of ~$2.75B and a 1‑year range of $1.03–$21.82; analysts have a consensus rating of "Moderate Buy" (consensus target $19.50) while several firms have raised targets (e.g., HC Wainwright $27, Stifel $24), and institutions now own about 79% of the stock after large recent buys.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 12,000 shares of the stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $20.11, for a total value of $241,320.00. Following the completion of the sale, the insider owned 112,622 shares in the company, valued at approximately $2,264,828.42. The trade was a 9.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Adam Crystal also recently made the following trade(s):
- On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00.
- On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.77, for a total value of $693,985.65.
- On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total value of $226,221.52.
Tango Therapeutics Price Performance
Shares of Tango Therapeutics stock opened at $19.26 on Friday. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -22.14 and a beta of 1.76. The firm's 50-day moving average is $14.29 and its two-hundred day moving average is $10.68. Tango Therapeutics, Inc. has a 1 year low of $1.03 and a 1 year high of $21.82.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, equities analysts expect that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have commented on TNGX. Stifel Nicolaus increased their price target on Tango Therapeutics from $15.00 to $24.00 and gave the company a "buy" rating in a research note on Monday, March 9th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Wedbush raised their target price on Tango Therapeutics from $15.00 to $19.00 and gave the company an "outperform" rating in a research report on Friday, March 6th. HC Wainwright boosted their price target on shares of Tango Therapeutics from $13.00 to $27.00 and gave the stock a "buy" rating in a report on Friday, March 6th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $18.00 target price on shares of Tango Therapeutics in a report on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.50.
Read Our Latest Research Report on TNGX
Institutional Investors Weigh In On Tango Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Adage Capital Partners GP L.L.C. lifted its position in Tango Therapeutics by 322.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company's stock valued at $93,986,000 after buying an additional 8,096,924 shares during the last quarter. Caligan Partners LP purchased a new position in shares of Tango Therapeutics during the fourth quarter worth $33,047,000. Goldman Sachs Group Inc. boosted its position in shares of Tango Therapeutics by 227.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company's stock worth $43,790,000 after buying an additional 3,432,939 shares during the period. Logos Global Management LP grew its stake in shares of Tango Therapeutics by 342.1% in the fourth quarter. Logos Global Management LP now owns 4,200,000 shares of the company's stock valued at $37,212,000 after buying an additional 3,250,000 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of Tango Therapeutics in the third quarter valued at $25,924,000. Hedge funds and other institutional investors own 78.99% of the company's stock.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
